Skip to main content

Table 2 Comparison between treatments with BBR/P/RR and EZE on plasma lipid concentrations in HCH patients. Six months follow-up

From: Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

 

BBR/P/RR

EZE

†P

Plasma lipids (mmo/L)

Baseline

On treatment

Percent change

Baseline

On treatment

Percent change

 

TC

7.63 ± 0.50

5.77 ± 0.49*

−24.2 ± 5.2

7.72 ± 0.49

6.25 ± 0.51*

−19.0 ± 4.6

< 0.001

LDL-C

5.36 ± 0.48

3.66 ± 0.48*

−31.7 ± 7.0

5.36 ± 0.52

4.00 ± 0.52*

−25.4 ± 6.4

< 0.001

HDL-C

1.55 ± 0.35

1.54 ± 0.37

−0.64 ± 7.2

1.57 ± 0.34

1.58 ± 0.35

+1.24 ± 6.9

NS

non-HDL-C

6.07 ± 0.54

4.22 ± 0.53*

−30.3 ± 6.5

6.15 ± 0.55

4.66 ± 0.58*

−24.2 ± 5.9

< 0.001

TG

1.46 (1.22-1.90)

1.12 (0.95-1.41)*

−19.5 ± 16.1

1.67 (1.24-2.12)

1.43 (1.08-1.80)*

−14.9 ± 11.5

NS

  1. Data are means ± SD or medians (interquartile ranges). *P < 0.001 vs baseline values (Student’s t test for paired data or Wilcoxon test); †P: significance of the differences between percent changes induced by BBR/P/RR and by EZE treatments (Student’s t test and Mann–Whitney test, respectively). NS: not significant.